G. C. Rabnott
University of Queensland
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by G. C. Rabnott.
Genes and Immunity | 2003
Ian A. Yang; S. L. Seeney; J. M. Wolter; E M Anders; Joseph G. McCormack; A. M. Tunnicliffe; G. C. Rabnott; Janet G. Shaw; Annette G. Dent; S. T. Kim; P. V. Zimmerman; Kwun M. Fong
Infection frequently causes exacerbations of chronic obstructive pulmonary disease (COPD). Mannose-binding lectin (MBL) is a pattern-recognition receptor that assists in clearing microorganisms. Polymorphisms in the MBL2 gene reduce serum MBL levels and are associated with risk of infection. We studied whether the MBL2 codon 54 B allele affected serum MBL levels, admissions for infective exacerbation in COPD and disease susceptibility. Polymorphism frequency was determined by PCR-RFLP in 200 COPD patients and 104 smokers with normal lung function. Serum MBL was measured as mannan-binding activity in a subgroup of 82 stable COPD patients. Frequency of COPD admissions for infective exacerbation was ascertained for a 2-year period. The MBL2 codon 54 B allele reduced serum MBL in COPD patients. In keeping, patients carrying the low MBL-producing B allele had increased risk of admission for infective exacerbation (OR 4.9, Pcorrected=0.011). No association of MBL2 genotype with susceptibility to COPD was detected. In COPD, serum MBL is regulated by polymorphism at codon 54 in its encoding gene. Low MBL-producing genotypes were associated with more frequent admissions to hospital with respiratory infection, suggesting that the MBL2 gene is disease-modifying in COPD. MBL2 genotype should be explored prospectively as a prognostic marker for infection risk in COPD.
Journal of the American College of Cardiology | 2002
Peter C. M. Molenaar; G. C. Rabnott; Ian A. Yang; Kwun M. Fong; Santiyagu M. Savarimuthu; Li Li; M. J. West; Fraser D. Russell
OBJECTIVE The goal of this study was to determine whether the cardiostimulant effects of the endogenous beta(1)-adrenergic receptor (AR) agonist, (-)-norepinephrine are modified by polymorphic (Serine49Glycine [Ser49Gly], Glycine389Arginine [Gly389Arg]) variants of beta(1)-ARs in the nonfailing adult human heart. BACKGROUND Human heart beta(1)-ARs perform a crucial role in mediating the cardiostimulant effects of (-)-norepinephrine. An understanding of the significance of Ser49Gly and Gly389Arg polymorphisms in the human heart is beginning to emerge, but not as yet in adult patients who have coronary artery disease (CAD). METHODS The potency and maximal effects of (-)-norepinephrine at beta(1)-ARs (in the presence of beta(2)-AR blockade with 50 nM ICI 118,551 [erythro-DL-1(7-methylindan-4-yloxy)-3-isopropylamino-butan-2-ol]) for changes in contractile force and shortening of contractile cycle duration were determined in human right atrium in vitro from 87 patients undergoing coronary artery bypass grafting who were taking beta-blockers before surgery. A smaller sample of patients (n = 20) not taking beta-blockers was also investigated. Genotyping for two beta(1)-AR polymorphisms (Ser49Gly and Gly389Arg) was determined from a sample of blood taken at the time of surgery. RESULTS (-)-Norepinephrine caused concentration-dependent increases in contractile force and reductions in time to reach peak force and time to reach 50% relaxation. There were no differences in the potency or maximal effects of (-)-norepinephrine in the right atrium from patients with different Ser49Gly and Gly389Arg polymorphisms. CONCLUSIONS The cardiostimulant effects of (-)-norepinephrine at beta(1)-ARs were conserved across Ser49Gly and Gly389Arg polymorphisms in the right atrium of nonfailing hearts from patients with CAD managed with or without beta-blockers.
Internal Medicine Journal | 2004
Renata L. Riha; Ian A. Yang; G. C. Rabnott; A. M. Tunnicliffe; Kwun M. Fong; P. V. Zimmerman
Abstract
Naunyn-schmiedebergs Archives of Pharmacology | 2003
Doreen Sarsero; Fraser D. Russell; James A. Lynham; G. C. Rabnott; Ian A. Yang; Kwun M. Fong; Li Li; Alberto J. Kaumann; Peter C. M. Molenaar
Circulation | 2002
Peter C. M. Molenaar; Fraser D. Russell; G. C. Rabnott; Ian A. Yang; Kwun M. Fong; Santiyagu M. Savarimuthu; Li Li; M. J. West
Lung Cancer | 2003
Annalese B. T. Semmler; Santiyagu M. Savarimuthu Francis; Alex Ruddy; G. C. Rabnott; Jessie M. Kelly; P. V. Zimmerman; Kwun M. Fong
BioInnovation: The Future of Medical Research | 2001
Peter C. M. Molenaar; Fraser D. Russell; G. C. Rabnott; I. A. Yang; Kwun M. Fong; M. J. West
Lung Cancer | 2000
R Gan; Ian A. Yang; P. V. Zimmerman; Kwun M. Fong; A Tunnicliffe; G. C. Rabnott; Edwina Duhig; Belinda E. Clarke
Fourteenth Annual North American Cystic Fibrosis Conference | 2000
R. Gan; Simon D. Bowler; S. L. Seeney; J. M. Wolter; Philip J. Masel; J. Bunting; A. M. Tunnicliffe; G. C. Rabnott; Ian A. Yang; Scott C. Bell
Pulmonary-Renal Interface | 1999
Ian A. Yang; R. Gan; A. M. Tunnicliffe; G. C. Rabnott; R. Slaughter; P. V. Zimmerman; Kwun M. Fong